Andrology
12 cases on exogenous testosterone alternatives with active fertility plans, post-cycle hypogonadism after anabolic steroid use, antioxidant supplementation for idiopathic male infertility, PDE5 inhibitor dosing strategy, erectile dysfunction with nitrate therapy, penile rehabilitation after prostatectomy, injection therapy escalation, ischemic priapism management, Peyronie's disease treatment, premature ejaculation pharmacotherapy, testosterone therapy after prostate cancer, and erythrocytosis on testosterone therapy — choose a case below to open its full multi-voice debate.
A single patient, referred to urology after a fertility workup flagged the testosterone gel his own doctor started. The disagreement isn't about whether he's hypogonadal — it's about which of three unproven alternatives to exogenous testosterone actually protects the fertility he still has.
A single patient, ten weeks off a self-administered anabolic steroid cycle, with libido and energy that haven't recovered on their own. The disagreement is whether his numbers justify pharmacologic intervention or whether time, which resolves most cases, deserves more patience than his own competition calendar allows.
A single patient, three years into an unexplained infertility workup, already seven months into an over-the-counter supplement he started on his own. The disagreement isn't just whether to stop it — it's whether anything empiric, supplement or injectable, belongs in its place.
A single patient with straightforward erectile dysfunction and a job that makes planning around a pill genuinely difficult. The disagreement has nothing to do with whether a PDE5 inhibitor will work — it's about which dosing strategy a schedule like his can actually sustain, a question no trial was built to answer.
A single patient whose angina regimen and sexual function cannot both be optimized as currently prescribed. The disagreement isn't about the nitrate rule itself, which nobody contests — it's about whether his actual anginal control can be restructured to make room for a PDE5 inhibitor at all.
A single patient, six weeks past nerve-sparing radical prostatectomy, asking for the daily pill he read protects erectile function long-term. The disagreement is less about whether to prescribe it than about what the group is honestly promising him if they do.
A single patient with vasculogenic erectile dysfunction who has already failed maximum-dose oral therapy. The disagreement is whether to step through the one FDA-approved injectable first or go straight to the compounded combination his diabetes makes more likely to actually work.
A single patient presenting with acute ischemic priapism after his usual home injection, arriving with blood pressure already elevated before any treatment starts. The disagreement isn't the first-line therapy — it's how many rounds of it to try, and on whom, before calling it a failure.
A single patient with stable-phase Peyronie's disease, intact erectile function, and no pain — the textbook candidate for collagenase by guideline criteria. The disagreement is whether “can still have intercourse” makes active treatment optional rather than indicated.
A single patient asking specifically for a drug that isn't approved in his own country. The disagreement isn't whether an SSRI will help — it's which one, at what schedule, and how directly to address where he first heard about the option he can't actually get.
A single patient, three years past radical prostatectomy with favorable pathology and undetectable PSA, now hypogonadal and asking for treatment. The disagreement isn't about the mechanism, or about whether a trial exists — it's about whether a twelve-week randomized result can carry the weight of an open-ended prescription.
A single patient whose testosterone therapy is working exactly as intended, except for the hematocrit it has also driven up — and a deadline that makes the usual slow recheck cycle a genuine constraint rather than a formality.